Modeling Sezary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

We describe the generation of physiologically-relevant SS preclinical models, comprehensive immunophenotyping of patient SS samples, clonal SS PDX outgrowth, and the highly effective anti-tumor activity of UCART2- plus NT-I7-mediated killing of SS cells in vivo using an NSG xenograft model. Ongoing studies involve treating primary SS and CTCL PDX models with UCART2 and NT-I7. These preclinical data validate the use of allogeneic "off-the-shelf" adoptive immunotherapy for the treatment of Sézary syndrome, while demonstrating the dramatic enhancement of CART efficacy using a dose-adjustable, clinic-ready long-acting interleukin-7 agonist given in an adjuvant setting.DisclosuresPark: NeoImmuneTech: Employment. Lee: NeoImmuneTech: Employment. Musiek: Seattle Genetics: Honoraria; Actelion: Other: Scientific Advisory Committee ; Kyowa Kirin: Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Staser, K. W., Cooper, M. L., Choi, J., Chukka, A., Ashami, K., Niswonger, J., Park, J., Lee, B. H., Li, S., Cashen, A. F., Musiek, A., DiPersio, J. F. Tags: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents: Immunologic approaches Source Type: research